Glycometabolism reprogramming: Implications for cardiovascular diseases

Guolong Peng; Jialong Yan; Linxi Chen; Lanfang Li

doi:10.1016/j.pbiomolbio.2023.03.003

Glycometabolism reprogramming: Implications for cardiovascular diseases

Prog Biophys Mol Biol. 2023 May:179:26-37. doi: 10.1016/j.pbiomolbio.2023.03.003. Epub 2023 Mar 23.

Authors

Guolong Peng¹, Jialong Yan¹, Linxi Chen², Lanfang Li³

Affiliations

¹ Institute of Pharmacy and Pharmacology, Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, University of South China, Hengyang, 421001, Hunan, China.
² Institute of Pharmacy and Pharmacology, Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, University of South China, Hengyang, 421001, Hunan, China. Electronic address: 1995001765@usc.edu.cn.
³ Institute of Pharmacy and Pharmacology, Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, University of South China, Hengyang, 421001, Hunan, China. Electronic address: 2005001782@usc.edu.cn.

PMID: 36963725
DOI: 10.1016/j.pbiomolbio.2023.03.003

Abstract

Glycometabolism is well known for its roles as the main source of energy, which mainly includes three metabolic pathways: oxidative phosphorylation, glycolysis and pentose phosphate pathway. The orderly progress of glycometabolism is the basis for the maintenance of cardiovascular function. However, upon exposure to harmful stimuli, the intracellular glycometabolism changes or tends to shift toward another glycometabolism pathway more suitable for its own development and adaptation. This shift away from the normal glycometabolism is also known as glycometabolism reprogramming, which is commonly related to the occurrence and aggravation of cardiovascular diseases. In this review, we elucidate the physiological role of glycometabolism in the cardiovascular system and summarize the mechanisms by which glycometabolism drives cardiovascular diseases, including diabetes, cardiac hypertrophy, heart failure, atherosclerosis, and pulmonary hypertension. Collectively, directing GMR back to normal glycometabolism might provide a therapeutic strategy for the prevention and treatment of related cardiovascular diseases.

Keywords: Cardiac metabolism; Cardiovascular disease; Glycometabolism reprogramming; Metabolic transformation.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Cardiomegaly
Cardiovascular Diseases*
Glycolysis
Humans
Metabolic Networks and Pathways
Oxidative Phosphorylation